The U.S. Food and Drug Administration (FDA) revised the boxed warning on the label for Yuflyma (adalimumab) effective July 15, 2026. This revision emphasizes the risks of serious infections and malignancy associated with the use of adalimumab, consistent with the class-wide understanding of TNF blockers.
Background
Adalimumab is a well-established biologic medication, available under several brand names and biosimilars, including Yuflyma. It belongs to a class of drugs known as TNF blockers, which are used to treat various autoimmune and inflammatory conditions. The drug works by blocking tumor necrosis factor (TNF), a protein involved in systemic inflammation. Given its mechanism, the potential for immune suppression and associated risks like serious infections and malignancies are important considerations for its use. Other biosimilars of adalimumab include Humira, Hulio, Yusimry, Idacio, Simlandi, Amjevita, Cyltezo, Hadlima, and Hyrimoz.
What this means
The FDA's revision of the boxed warning for Yuflyma (adalimumab) reinforces critical safety information for healthcare providers and patients. Boxed warnings, also known as black box warnings, are the strongest warnings the FDA requires for prescription drugs when there is reasonable evidence of a serious hazard. This update specifically calls attention to the increased risk of serious infections, which can lead to hospitalization, and the potential for malignancy. Clinicians prescribing adalimumab and its biosimilars should continue to carefully assess patient risk factors for these adverse events and monitor patients throughout treatment, as outlined in the full prescribing information.
Source
This information was sourced from the U.S. Food and Drug Administration (FDA), detailing a label revision for Yuflyma (adalimumab) effective July 15, 2026. The updated prescribing information is available on dailymed.nlm.nih.gov.